Critical Contrast: Acusphere (OTCMKTS:ACUS) & Surrozen (NASDAQ:SRZN)

Surrozen (NASDAQ:SRZN) and Acusphere (OTCMKTS:ACUS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

Profitability

This table compares Surrozen and Acusphere’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Surrozen	-4,810.50%	N/A	-154.08%
Acusphere	N/A	N/A	N/A

Analyst Ratings

This is a summary of current recommendations and price targets for Surrozen and Acusphere, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surrozen	2	0	3	1	2.50
Acusphere	0	0	0	0	0.00

Surrozen presently has a consensus target price of $42.00, suggesting a potential upside of 68.54%. Given Surrozen’s stronger consensus rating and higher probable upside, analysts plainly believe Surrozen is more favorable than Acusphere.

Valuation & Earnings

This table compares Surrozen and Acusphere”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surrozen	$3.48 million	83.14	-$242.03 million	($37.59)	-0.66
Acusphere	N/A	N/A	N/A	N/A	N/A

Acusphere has lower revenue, but higher earnings than Surrozen.

Institutional & Insider Ownership

66.6% of Surrozen shares are owned by institutional investors. 31.7% of Surrozen shares are owned by insiders. Comparatively, 4.6% of Acusphere shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Surrozen beats Acusphere on 7 of the 9 factors compared between the two stocks.

About Surrozen

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

About Acusphere

Acusphere, Inc. operates as a specialty pharmaceutical company that develops and commercializes cardiovascular drugs. It offers Imagify (perflubutane polymer microspheres), a cardiovascular drug that evaluates myocardial perfusion and detects coronary artery disease. It provides Imagify as an injectable suspension. The company was formerly known as Polymers For Medicine, Inc. and changed its name to Acusphere, Inc. in March 2004. Acusphere, Inc. was founded in 1993 and is based in Watertown, Massachusetts.